Precigen, Inc.
PAPZIMEOS
Recurrent Respiratory Papillomatosis (RRP)
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for PAPZIMEOS in Recurrent Respiratory Papillomatosis (RRP) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 17h ago
“The Company initiated an open-label study to evaluate safety, vector shedding, and retreatment efficacy of zopapogene imadenovec in adults with RRP (clinical trial identifier: NCT06538480 ).”